Lebrikizumab is the most recently approved biologic for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years or older who are candidates for systemic therapy. To date, real-world data investigating the effectiveness of lebrikizumab in pruritus are lacking. In this context, the aim of our study was to evaluate the effectiveness (particularly on pruritus) of lebrikizumab in patients with atopic dermatitis treated for at least 16 weeks in a real-life setting.
Real-world effectiveness of lebrikizumab on pruritus in moderate-to-severe atopic dermatitis: preliminary data from a single-centre real-life experience
Patruno, Cataldo;
2025-01-01
Abstract
Lebrikizumab is the most recently approved biologic for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years or older who are candidates for systemic therapy. To date, real-world data investigating the effectiveness of lebrikizumab in pruritus are lacking. In this context, the aim of our study was to evaluate the effectiveness (particularly on pruritus) of lebrikizumab in patients with atopic dermatitis treated for at least 16 weeks in a real-life setting.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
